Aviva PLC Sells 36,633 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Aviva PLC decreased its position in MiMedx Group, Inc. (NASDAQ:MDXG) by 35.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,346 shares of the company’s stock after selling 36,633 shares during the quarter. Aviva PLC’s holdings in MiMedx Group were worth $629,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of MDXG. IMG Wealth Management Inc. acquired a new stake in MiMedx Group in the 4th quarter valued at $28,000. SkyView Investment Advisors LLC grew its holdings in shares of MiMedx Group by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock valued at $77,000 after acquiring an additional 3,000 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of MiMedx Group by 6.3% in the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock valued at $328,000 after acquiring an additional 3,292 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in MiMedx Group by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company’s stock worth $4,849,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Van ECK Associates Corp acquired a new position in MiMedx Group during the fourth quarter valued at approximately $40,000. 79.15% of the stock is currently owned by institutional investors.

Insider Buying and Selling at MiMedx Group

In related news, CAO William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the sale, the chief accounting officer now directly owns 494,774 shares of the company’s stock, valued at approximately $3,859,237.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares of the company’s stock, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 144,018 shares of company stock worth $1,130,312 over the last ninety days. Insiders own 1.30% of the company’s stock.

MiMedx Group Price Performance

Shares of NASDAQ MDXG opened at $6.86 on Friday. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average price is $7.89 and its two-hundred day moving average price is $7.98. The company has a market cap of $1.01 billion, a PE ratio of 12.47 and a beta of 1.74. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The business had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. On average, analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on MDXG. StockNews.com raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 4th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.